InvestorLens

PTGX — PROTAGONIST THERAPEUTICS INC

Public company

Sign in to save4 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying PTGX?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Net accumulation · 2 buying vs 0 selling last quarter
63
Macro Tailwind
Macro conditions are mixed for this sector
56
Why? — Evidence & Confidence ▾

Of 2 tracked investors who changed their PTGX position last quarter, 2 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 56/100 in a Overheat regime).

Supporting evidence
  • +2 tracked investors added or increased positions last quarter (Ray Dalio, Stanley Druckenmiller)
  • +4 tracked investors reported holding PTGX at their latest filing
  • +Macro Health is 56/100 in a Overheat regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.

About PROTAGONIST THERAPEUTICS INC (PTGX)

PROTAGONIST THERAPEUTICS INC (PTGX) appears in the most recent 13F filings of 4 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $169M. Across recent filings, tracked investors recorded 6 new positions, 2 increased, 0 reduced, and 3 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in PTGX

73
/100
Institutional Accumulation
Added / Increased8
Reduced0
Exited3
BearishBullish
Crowded Trade Score™

How many top investors track PTGX

27
/100
Emerging Interest
4investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

PTGX Ownership Composition

How PROTAGONIST THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Macro
83% of tracked value
Institutions
4
tracked investors
Total Reported
$33.1M
combined 13F value
Types2
  • Macro83.0%
  • Multi-Strategy / Quant17.0%
Macro(3)
83.0%
Multi-Strategy / Quant(1)
17.0%

Tracked investors currently reporting PTGX

3 tracked investors have since exited this position — listed separately below.

  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    45.8K
    Value
    $5.6M
    % Portfolio
    0.00%
  • Stanley DruckenmillerJun 30, 2026
    Duquesne Family Office
    Shares
    208.9K
    Value
    $25.6M
    % Portfolio
    0.49%
  • Paul Tudor JonesJun 30, 2026
    Tudor Investment Corp
    Shares
    5.8K
    Value
    $711K
    % Portfolio
    0.00%
  • Ray DalioJun 30, 2026
    Bridgewater Associates
    Shares
    9.3K
    Value
    $1.1M
    % Portfolio
    0.00%

Previously held PTGX

These investors reported PTGX in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Izzy EnglanderMillennium Management17.4K$1.5MDec 31, 2025
Steve CohenPoint72 Asset Management214.9K$9.7MSep 30, 2024
George SorosSoros Fund Management100K$8.7MDec 31, 2025

Recent activity

Frequently asked questions

How many institutional investors hold PTGX?
4 tracked institutional investors disclosed a position in PTGX (PROTAGONIST THERAPEUTICS INC) in their most recent 13F filing.
Who is the largest institutional holder of PTGX?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in PTGX, valued at $169M.
Did institutional ownership of PTGX increase or decrease?
Across recent 13F filings, tracked investors recorded 6 new positions, 2 increased, 0 reduced, and 3 fully exited PTGX.
Where does this PTGX ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.